Letosteine is a mucolytic[1] patented (U.S. patent 6987120) by Piero del Soldato of Milan, Italy.[2] He filed his application in 2000.

Letosteine
Clinical data
Trade namesViscotiol
Other names2-[2-(ethoxycarbonylmethylsulfanyl)ethyl]-1,3-thiazolidine-4-carboxylic acid
Routes of
administration
Oral (gastroresistant capsules)
ATC code
Identifiers
  • 2-[2-(2-ethoxy-2-oxoethyl)sulfanylethyl]-1,3-thiazolidine-4-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.053.509 Edit this at Wikidata
Chemical and physical data
FormulaC10H17NO4S2
Molar mass279.37 g·mol−1
3D model (JSmol)
  • O=C(O)C1NC(SC1)CCSCC(=O)OCC
  • InChI=1S/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14) checkY
  • Key:IKOCLISPVJZJEA-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z (November 2014). "Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial". Die Pharmazie. 69 (11): 842–9. PMID 25985582.
  2. ^ US 6987120, del Soldato P, "Pharmaceutical compounds", issued 17 January 2006, assigned to Nicox SA